Physician profile
Carmelo Cuffari
NPI 1336184225
$60,675.09
in general payments reported to CMS, 2019-2025
10 companies · $17.03 in 2025
The $17.03 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $13K · 2021: $22K · 2022: $770 · 2023: $565 · 2024: $105 · 2025: $17.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $686.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51,356.08 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $7,763.83 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $608.86 | 2022 | |
| Abbott Laboratories | $441.20 | 2019-2023 | |
| Genzyme Corporation | $225.21 | 2023-2024 | |
| Shire North American Group INC | $200.00 | 2019 | |
| Janssen Biotech, INC. | $44.76 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $17.90 | 2024 | Dupixent |
| Sobi, INC | $17.25 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelo Cuffari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.